Studies of DaxibotulinumtoxinA Injection to Treat Forehead Lines and Crow’s Feet Produce Positive Results, Revance Announces

Revance Therapeutics Incannounces results for two Phase 2a open-label, dose escalation studies of its investigational drug candidate DaxibotulinumtoxinA for Injection in the treatment of dynamic forehead lines (FHL) following glabellar (frown) line injections and lateral canthal lines (LCL), commonly known as crow’s feet.